Osimertinib, a third-generation EGFR TKI, has become a first-line therapy for advanced NSCLC patients with sensitizing EGFR mutations, including the T790M mutation which confers resistance to earlier generation TKIs. Here, EGFR is linked to non-small cell lung carcinoma.